Immune Shield Protocol
Comprehensive immune system support, antimicrobial defense, and gut-immune axis optimization
Peptide Stack
Preparation
Reconstitute all peptides with bacteriostatic water. Store at 2-8°C and use within 2-4 weeks. Rotate injection sites to prevent irritation.
Administration
Thymosin Alpha-1 and LL-37 twice weekly (can be same days). BPC-157 daily. All subcutaneous injections. Maintain consistent schedule for optimal immune modulation.
Monitoring
Track frequency of illness, recovery time from infections, energy levels, and gut health. Consider baseline and follow-up blood work for immune markers (white blood cell count, lymphocytes).
Expected Timeline
Week 1-2: Initial immune activation. Week 3-6: Enhanced resistance to infections. Week 7-10: Sustained immune function and gut health improvements. Benefits continue after protocol completion.
Research Basis
Thymosin Alpha-1 enhances adaptive immunity and T-cell function. LL-37 provides innate antimicrobial defense. BPC-157 supports gut-immune axis. Together, they provide comprehensive immune support.
Safety Considerations
- Do not use if you have autoimmune conditions without medical supervision
- Avoid during pregnancy or breastfeeding
- Monitor for signs of immune overactivation
- Consult with a healthcare professional before starting
- This protocol is for research and educational purposes only
Protocol Overview
A comprehensive immune support protocol using Thymosin Alpha-1 for adaptive immunity, LL-37 for innate antimicrobial defense, and BPC-157 for gut-immune axis support.
Duration: 10 weeks Peptides: 3 Experience Level: Beginner
Peptide Stack
THYMOSIN-ALPHA-1
- Dose: 1.6 mg
- Frequency: twice weekly
- Timing: any time of day
LL-37
- Dose: 2-5 mg
- Frequency: twice weekly
- Timing: any time of day
BPC-157
- Dose: 250 mcg
- Frequency: daily
- Timing: morning
Preparation
Reconstitute all peptides with bacteriostatic water. Store at 2-8°C and use within 2-4 weeks. Rotate injection sites to prevent irritation.
Administration
Thymosin Alpha-1 and LL-37 twice weekly (can be same days). BPC-157 daily. All subcutaneous injections. Maintain consistent schedule for optimal immune modulation.
Monitoring
Track frequency of illness, recovery time from infections, energy levels, and gut health. Consider baseline and follow-up blood work for immune markers (white blood cell count, lymphocytes).
Expected Timeline
Week 1-2: Initial immune activation. Week 3-6: Enhanced resistance to infections. Week 7-10: Sustained immune function and gut health improvements. Benefits continue after protocol completion.
Research Basis
Thymosin Alpha-1 enhances adaptive immunity and T-cell function. LL-37 provides innate antimicrobial defense. BPC-157 supports gut-immune axis. Together, they provide comprehensive immune support.
Safety Considerations
- Do not use if you have autoimmune conditions without medical supervision
- Avoid during pregnancy or breastfeeding
- Monitor for signs of immune overactivation
- Consult with a healthcare professional before starting
- This protocol is for research and educational purposes only
Disclaimer: This protocol is for educational and research purposes only. It is not medical advice. Consult with a qualified healthcare professional before starting any peptide protocol. These compounds are not approved by the MHRA for human therapeutic use.
Important Disclaimer: This protocol is for educational and research purposes only. It is not medical advice. Consult with a qualified healthcare professional before starting any peptide protocol. These compounds are not approved by the MHRA for human therapeutic use.